Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/08—Drugs for disorders of the urinary system of the prostate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/06—Antiarrhythmics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
  • C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
  • C07C303/40—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
  • C07D279/02—1,2-Thiazines; Hydrogenated 1,2-thiazines
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Definitions

• the present invention relates to improved syntheses of known and novel benzothiazine dioxide which are potent and selective endothelin antagonists.
• the processes of the instant invention are improved over those recited in United States Patent 5,599,811 which is hereby incorporated by reference.
• the compounds of the instant invention exhibit very significant improvements over those described in United States Patent 5,599,811. These improvements include: binding affinity to the ET ⁇ receptor, ET ⁇ selectivity, functional activity, long pharmacokinetic half-life, high bioavailability, in vivo activity in inhibiting the pressor effect caused by bET-1, oral activity with relatively long duration of action, and efficacy in acute hypoxic pulmonary hypertension in rats.
• the processes of the instant invention provide more facile syntheses with higher yields. They are short, clean, reproducible and no tedious chromatography is needed. Moreover, the processes are scaleable and therefore useful for large- scale development.
• the present invention also relates to antagonists of endothelin useful as pharmaceutical agents, to pharmaceutical compositions which include these compounds and a pharmaceutically acceptable carrier, and to pharmaceutical methods of treatment. More particularly, the compounds of the present invention are antagonists of endothelin useful in treating elevated levels of endothelin, acute and chronic renal failure, essential renovascular malignant and pulmonary hypertension, cerebral infarction and cerebral ischemia, cerebral vasospasm, cirrhosis, septic shock, congestive heart failure, endotoxic shock, subarachnoid hemorrhage, arrhythmias, asthma, preeclampsia, atherosclerotic disorders including Raynaud's disease and restenosis, angina, cancer, benign prostatic hyperplasia, ischemic disease, gastric mucosal damage, hemorrhagic shock, ischemic bowel disease, and diabetes.
• the compounds will be useful in cerebral ischemia or cerebral infarction resulting from a range of conditions such as thromboembolic or hemorrhagic stroke, cerebral vasospasm, head injury, hypoglycemia, cardiac arrest, status epilepticus, perinatal asphyxia, anoxia such as from drowning, pulmonary surgery, and cerebral trauma.
• This invention is improved processes for the preparation of compounds of Formula 1
• R ] is hydrogen, alkyl, or alkoxy
• R2 is hydrogen or alkoxy
• R3 is alkyl or alkoxy
• R2 and R3 may be joined to form a ring / ⁇ O ;
• R4 is hydrogen or alkyl
• R5 is hydrogen, alkyl, alkoxy, halogen at the 2 or 3, or 4, or 5 positions or
• R5 is a 3,4-methylenedioxo; and Rg is CF3, halogen, alkyl, benzyl, phenyl, hydroxy, or pyrrole comprising: a) alkylating a compound of formula A
• the free acid of Formula 1 is obtained by sponification of the ester with, for example, LiOH in THF/MeOH or in dioxane. Any strongly alkaline solution in methanol can be used.
• Compounds of the invention are those prepared by the above process, especially those selected from:
• the invention is also a process for the preparation of a compound of Formula 1
• the free acid of Formula 1 is obtained by sponification of the ester.
• the invention is also a process for the preparation of a compound of formula B
• step b) lithiating the product of step a) above at low temperatures and quenching with CO2 to form a compound of formula G
• step b) treating the product of step b) above with acetic anhydride and a catalytic amount of methanesulfonic acid to produce a compound of formula H
• step d) treating the product of step c) above with NaOMe followed by methyl bromoacetate to produce a compound B as above.
• Compound B is carried over to Formula 1 as described before.
• Compounds of the invention are those prepared from the above process, especially 4-(7-Ethyl-benzo[ 1 ,3]dioxol-5-yl)- 1 , 1 -dioxo-2-(2-trifluoromethyl- phenyl)-1.2-dihydro-l ⁇ 6-benzo[e][l,2]thiazine-3 -carboxylic acid methyl ester.
• the sodium and potassium salts of the above compound are preferred.
• the invention is also a process for the preparation of a compound of
• the invention is also a process for the preparation of a compound of Formula 1 comprising: a) reacting 2-methylanaline with benzenesulfonyl chloride to produce a compound of formula F
• step b) treating the product of step a) above with n-butyl lithium and then with 3-methoxy-4,5-methylenedioxybenzaldehyde to produce a compound of formula M
• step b) treating the product of step b) above with sodium hydride followed by methyl bromoacetate to produce a compound of formula N
• step d) cyclizing the product of step d) above by treating with a base or a
• Compounds of the invention are those prepared by the above process, especially 4-(7-Methoxy-benzo[ 1 ,3]dioxol-5-yl)- 1 , 1 -dioxo-2-o-tolyl- 1 ,2-dihydro- l ⁇ 6-benzo[e][l,2]thiazine-3 -carboxylic acid methyl ester.
• the invention is also a pharmaceutical composition of the compounds of Formula 1 above comprising a therapeutically effective amount of a compound of Formula 1 in admixture with a pharmaceutically acceptable carrier.
• the compounds of the invention are useful in inhibiting elevated levels of endothelin comprising administering to a host in need thereof a therapeutically effective amount of a compound of Formula I in unit dosage form. They are also useful in treating subarachnoid hemorrhage, essential, renovascular. malignant and pulmonary hypertension, congestive heart failure, cerebral ischemia, or cerebral infarction.
• alkyl means a straight or branched hydrocarbon radical having from 1 to 12 carbon atoms unless otherwise specified and includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, allyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, undecyl, and dodecyl.
• "Halogen” is fluorine, chlorine, bromine or iodine.
• alkoxy is an alkyl group as described above attached by oxygen to the rest of the molecule. Preferred alkoxy group are from 1 to 4 carbon atoms.
• the host receiving a compound of the invention is a mammal, particularly a human.
• the compounds of Formula 1 above may be prepared by several methods. These methods are illustrated in Schemes 1 through 3 and in a detailed manner by way of illustration in the example section of the specification.
• Scheme 1 illustrates the general procedure for the preparation of the compounds of Formula 1.
• Synthesis of the intermediate A was described in United States Patent 5,599,811. Reaction of methyl-2-(chlorosulfonyl)benzoate with an aniline in methylene chloride with 1 to 2 equivalents of pyridine and a catalytic amount of DMAP at room temperature overnight affords the sulfonamide A. The reaction can also be run using neat pyridine as the solvent. Alkylation of A was achieved by treatment of A with sodium hydride in DMF followed by reaction with methyl bromoacetate to give intermediate B. B can be converted to the key intermediate C via Claisen cyclization which were found to be promoted by at least two different catalysts.
• condition I the intermediate B in methylene chloride was added to a solution of 2 equivalents of ⁇ CI4 in methylene chloride at -78°C followed by the treatment with 2.2 equivalents of triethyl amine.
• the reaction was quenched with IN HC1 followed by aqueous work up and recrystallization.
• condition II is similar to condition I with the use of 1.2 equivalents of TiCl (OTf)2 (Bull. Chem. Soc. Jpn, 1989;62: 1917) followed by quench with pH 7 phosphate buffer and extractive workup.
• the cyclized enol C was treated with triflic anhydride in solvents such as methylene chloride in the presence of 2 to 5 equivalents of pyridine for 1 to 5 hours to afford the triflate D quantitatively.
• the coupling reaction was carried out between the triflate D and the corresponding boronic acid in DMF and toluene (ratio of 1 :4) in the presence of 10 mole% tetrakis(triphenyl phosphine)palladium as the catalyst and 1 to 2 equivalents of potassium carbonate under reflux for 2 hours.
• the reaction mixture was filtered, and the product was purified by column chromatography or by recrystallization.
• the free acid of the Formula 1 was obtained by sponification of the ester with aqueous LiOH in THF/MeOH or in dioxane.
• the free acid can be converted, for example, to a sodium or potassium salts, which are much more soluble in H2O, by treating it with one equivalent of NaOH or KOH in MeOH followed by recrystallization.
• Scheme la indicates an alternative assembly reaction for the formation of the 4-aryl benzothiazine derivatives exemplified by intermediate E.
• the coupling reaction was conducted by reacting an aryl zinc bromide, prepared by treating an aryl bromide with one equivalent of n-butyl lithium in THF followed by zinc bromide, with the intermediate D in the presence of 10% tetrakis(triphenylphosphine)palladium as the catalyst under reflux for 2 hours.
• the Scheme 1 was further modified to replace a relatively expensive starting material, methyl-2-(chlorosulfonyl)benzoate, with phenyl sulfonyl chloride.
• the process (Scheme lb) is proven to be more economical and workable in large scale.
• the sulfonamide F was formed by reacting the phenyl sulfonyl chloride with one equivalent of aniline under similar condition as described for A or using an equal amount of saturated sodium bicarbonate solution in THF. It was lithiated with r ⁇ -BuLi at low temperature and quenched with CO2 to form the intermediate G in 92% yield. The acid G was then treated with acetic anhydride with a catalytic amount of methanesulfonic acid to form the intermediate H. This cyclic compound was treated with NaOMe followed by quenching with methyl bromoacetate to form B directly in 71% yield.
• Scheme 3 illustrates an alternative synthesis that has been successfully utilized in the synthesis of certain analogs. This is illustrated by the synthesis of Example 8.
• Intermediate F was treated with 2 equivalents of n-butyl lithium at -78°C to generate the dianion.
• a solution of 3-methoxy-4,5- methylenedioxybenzaldehyde in tetrahydrofuran was added to the reaction mixture. It was then warmed to 0°C over 1.5 hours.
• Aqueous work up afforded M which was treated with sodium hydride followed by methyl bromoacetate to give N. Jones oxidation of N was carried out in acetone to afford the keto ester O in 60% yield.
• the cyclization of O can be promoted by a base or a Lewis acid such as titanium bis-chloro-bis-triflate in an appropriate solvent such as methylene chloride.
• the ester E was purified by column chromatography to provide pure sample in 53% yield.
• the esters synthesized through this route were sponified according to procedures described in Scheme 1.
• Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines.
• metals used as cations are sodium, potassium, magnesium, calcium, and the like.
• suitable amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge SM, et al., "Pharmaceutical Salts," Journal of Pharmaceutical Science, 1977;66: 1-19).
• the base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner.
• Certain of the compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms.
• the solvated forms, including hydrated forms are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention.
• Certain of the compounds of the present invention possess one or more chiral centers and each center may exist in the R or S configuration.
• the present invention includes all enantiomeric and epimeric forms as well as the appropriate diastereomeric mixtures thereof.
• the compounds of Formula 1 are valuable antagonists of endothelin.
• the tests employed indicate that compounds of the invention possess endothelin antagonist activity. Thus, the compounds were tested for their ability to inhibit
• the following cultured cells were used in binding experiments: Ltk'cells expressing recombinant human ET ⁇ R (HET ⁇ ), and CHO-K1 cells expressing recombinant human ET ⁇ R (HET ⁇ ).
• Membranes were prepared from cultured cells by lysing cells in cold lysis buffer (5 mM HEPES, 2 mM EDTA, pH 7.4) and homogenizing with a Dounce "A" homogenizer. The homogenate was centrifuged at 30,000 x g for 20 minutes at 40°C. Membrane pellets were suspended in cold buffer containing
• Competing binding assays were initiated by combining membranes, [125FJ-ET-1 (40 pM) and the competing ligand in a final volume of 250 ⁇ L and incubating for 2 hours at 37°C. The assay was terminated by filtration over Whatman GF/B filters which were presoaked with 50 mM Tris, pH 7.4 containing
• Antagonist activity is measured by the ability of added compounds to reduce endothelin-stimulated arachidonic acid release in cultured vascular smooth muscle cells.
• LM HJArachidonic Acid Loading Media
• Confluent monolayers of cultured rabbit renal artery vascular smooth muscle cells were incubated in 0.5 mL of the LM over 18 hours, at 37°C, in 5% CO2- The LM was aspirated and the cells were washed once with the assay buffer (Hank's BSS + 10 mM HEPES + fatty acid-free BSA (1 mg/mL)), and incubated for 5 minutes with 1 mL of the prewarmed assay buffer. This solution was aspirated, followed by an additional
• pulmonary arteries 4.0 g pulmonary arteries; the rings were left for 90 minutes to equilibrate.
• Vascular rings were tested for lack of functional endothelium (ie, lack of an endothelium-dependent relaxation response to carbachol (1.0 nM) in norepinephrine (0.03 nM) contracted rings.
• Agonist peptides, ET-1 (femoral), and S6c (pulmonary), were cumulatively added at 10-minute intervals. The ET antagonists were added 30 minutes prior to adding the agonist.
• the peak arterial pressor response in rats pre-treated with selected compounds of invention compared to vehicle-treated rats is used to determine activity expressed as % inhibition.
• activity selected compounds of invention was dose 10 minutes before the bET-1 challenge, and for oral activity selected compounds of invention was administered via oral gavage 8 or 24 hours before the bET-1 challenge.
• ETA blockade with oral Example 10 was demonstrated through inhibition of bET-1 pressor response in the rat (10 mg/kg produced 44% inhibition at 8 hours postdose and 30 mg/kg produced a 48% inhibition at 24 hours postdose) and dog (15 mg/kg produced 25% inhibition at 24 hours postdose).
• Example 10 was well absorbed orally both in rat and dog. Terminal elimination t'As were determined to be 8.5 and 2.2 hours in rat and dog, respectively, and bioavailability is 77% and 100% in rat and dog.
• the compounds of the present invention can be prepared and administered in a wide variety of oral and parenteral dosage forms.
• the compounds of the present invention can be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally.
• the compounds of the present invention can be administered by inhalation, for example, intranasally. Additionally, the compounds of the present invention can be administered transdermally.
• dosage forms may comprise as the active component, either a compound of Formula 1 or a corresponding pharmaceutically acceptable salt of a compound of Formula 1.
• pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
• a solid carrier can be one or more substances which may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
• the carrier is a finely divided solid which is in a mixture with the finely divided active component.
• the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
• the powders and tablets preferably contain from five or ten to about seventy percent of the active compound.
• Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like.
• the term "preparation" is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it.
• cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.
• a low melting wax such as a mixture of fatty acid glycerides or cocoa butter
• the active component is dispersed homogeneously therein, as by stirring.
• the molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.
• Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water propylene glycol solutions.
• liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.
• Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing and thickening agents as desired.
• Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents. Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
• the pharmaceutical preparation is preferably in unit dosage form.
• the preparation is subdivided into unit doses containing appropriate quantities of the active component.
• the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules.
• the unit dosage form can be a capsule, table, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
• the quantity of active component in a unit dose preparation may be varied or adjusted from 0.1 mg to 100 mg preferably 0.5 mg to 100 mg according to the particular application and the potency of the active component.
• the composition can, if desired, also contain other compatible therapeutic agents.
• the compounds utilized in the pharmaceutical method of this invention are administered at the initial dosage of about 0.01 mg to about 100 mg/kg daily.
• a daily dose range of about 0.01 mg to about 10 mg/kg is preferred.
• the dosages may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being employed. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day, if desired. The following nonlimiting examples illustrate the preferred methods for preparing the compounds of the invention.
• EXAMPLE ID 1 1 -Dioxo-4-(trifluoro-methanesulfonyloxy)-2-(2-trifluoromethyl-phenyl)- 1.2-dihydro-l ⁇ " ' benzo[e1[l,2 "
• dichloromethane 150 mL was added 4-hydroxy-l,l-dioxo- 2-(2-trifluoromethyl-phenyl)- 1 ,2-dihydro- 1 ⁇ -benzo[e] [ 1 ,2]thiazine-3-carboxylic acid methyl ester, (13.1 g, 32 mmol).
• the solvent was removed in vacuo, and the suspension was extracted with ethyl ether.
• the ether phase was washed with brine, and the product was extracted into 0.5N NaOH.
• the NaOH solution was washed with ethyl ether and acidified to pH 1 with 2N HCl.
• the acidified aqueous phase was extracted with ethyl ether, washed with brine, dried over anhydrous magnesium sulfate, filtered, and evaporated to a brown solid, 7.43 g, 40% yield.
• the material was of sufficient purity to be used in subsequent preparations.
• Example 4E was prepared in the same way as illustrated in Example IE in
• N-o-tolyl-benzenesulfonamide 4.95 g, 20 mmol.
• n-butyllithium 1.6 M, 25 mL in hexane
• the free acid 10 (32.1 g, 62 mmol) was dissolved in 100 mL of MeOH. To this was added 62 mL of IN KOH. After stirring at room temperature for 1 hour, most of the MeOH was removed by rotatory evaporator. EtOH was then added
• EXAMPLE 13E 4-Benzo[ 1 ,31dioxol-5-yl-2-f 2-ethyl-phenyl)- 1 , 1 -dioxo- 1 ,2-dihydro- 1 ⁇ - benzo [el [l,21thiazine-3 -carboxylic acid methyl ester Prepared in the same way as illustrated in Example IE in 81% yield.
• the triflate was prepared according to procedures described in
• Example ID The coupling reaction was carried out in the same way as illustrated in Example 12L in 57% yield.
• the coupling reaction was carried out with 20D and the corresponding boronic acid in the same way as illustrated in Example IE in 80% yield.
• the product was dissolved in DMF and was treated with 20% Pd/C under 50 atm pressure for 2 days to obtain 20E in 20% yield and recovery of the rest as the starting material.
• the NMR spectra and elemental analysis were consistent with the structure.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• General Chemical & Material Sciences (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Urology & Nephrology (AREA)
• Diabetes (AREA)
• Pulmonology (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Hospice & Palliative Care (AREA)
• Endocrinology (AREA)
• Vascular Medicine (AREA)
• Emergency Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
• Plural Heterocyclic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Priority Applications (16)

Applications Claiming Priority (4)

Related Child Applications (3)

Publications (1)

Family

ID=26737251

Family Applications (1)

Country Status (24)

Cited By (6)

Families Citing this family (4)

Citations (5)

Family Cites Families (6)

• 1998
  • 1998-08-13 AU AU90196/98A patent/AU759169B2/en not_active Ceased
  • 1998-08-13 WO PCT/US1998/016856 patent/WO1999012916A1/en not_active Ceased
  • 1998-08-13 KR KR1020007002339A patent/KR20010023686A/ko not_active Withdrawn
  • 1998-08-13 EP EP98942061A patent/EP1009743B1/en not_active Expired - Lifetime
  • 1998-08-13 NZ NZ502670A patent/NZ502670A/xx unknown
  • 1998-08-13 ES ES98942061T patent/ES2221191T3/es not_active Expired - Lifetime
  • 1998-08-13 JP JP2000510724A patent/JP2001515893A/ja not_active Abandoned
  • 1998-08-13 HU HU0003689A patent/HUP0003689A3/hu unknown
  • 1998-08-13 AT AT98942061T patent/ATE270281T1/de not_active IP Right Cessation
  • 1998-08-13 CA CA002296358A patent/CA2296358A1/en not_active Abandoned
  • 1998-08-13 PT PT98942061T patent/PT1009743E/pt unknown
  • 1998-08-13 PL PL98338983A patent/PL338983A1/xx unknown
  • 1998-08-13 IL IL13405798A patent/IL134057A0/xx unknown
  • 1998-08-13 BR BR9812431-5A patent/BR9812431A/pt not_active Application Discontinuation
  • 1998-08-13 US US09/445,504 patent/US6265399B1/en not_active Expired - Fee Related
  • 1998-08-13 DE DE69824863T patent/DE69824863T2/de not_active Expired - Fee Related
  • 1998-09-03 MY MYPI98004024A patent/MY116277A/en unknown
  • 1998-09-04 PE PE1998000822A patent/PE116699A1/es not_active Application Discontinuation
  • 1998-09-04 UY UY25168A patent/UY25168A1/es not_active IP Right Cessation
  • 1998-09-04 AR ARP980104414A patent/AR017056A1/es unknown
  • 1998-09-04 CO CO98050781A patent/CO4970725A1/es unknown
  • 1998-10-28 TW TW087114760A patent/TW508355B/zh not_active IP Right Cessation
• 2000
  • 2000-01-21 IS IS5356A patent/IS5356A/is unknown
  • 2000-03-02 NO NO20001078A patent/NO20001078L/no unknown
  • 2000-08-07 US US09/633,720 patent/US6252070B1/en not_active Expired - Fee Related
• 2001
  • 2001-03-27 US US09/818,394 patent/US6440962B2/en not_active Expired - Fee Related
  • 2001-12-05 US US10/006,589 patent/US6545150B2/en not_active Expired - Fee Related
• 2002
  • 2002-06-03 US US10/161,569 patent/US20030073684A1/en not_active Abandoned

Patent Citations (6)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events